Applied Cannabis Research (ACR), a division of Southern Cannabis Holdings (SCH), has launched a new Observational Study to assess the impact of THC-based medications for sufferers of Cachexia and is pleased to announce that the medication and TGA SAS-B application process will be fully funded until 30th April 2020 on compassionate grounds.
Key Highlights:
Applied Cannabis Research (ACR) is conducting a 6-month study investigating the impact of THC-dominant medication on Cachexia.
Participant recruitment will be over a 10 week period from 17th Feb – 24th April 2020
Medications and one-time TGA SAS B application costs are funded prior to April 30th 2020
Medications after April 30th 2020 will be prescribed and dispensed at normal retail prices
GP consultation fees are applicable throughout the study
Study will be conducted by SCH division CA Clinics.
Further study is important to determine whether patients with cachectic conditions such as cancer-related anorexia-cachexia syndrome (CACS) see an improvement in appetite and quality of life using THC-dominant medical treatment.
ACR is working together with CA Clinics, that will coordinate the recruitment and assessment of suitable patients. After the 10 week recruitment period, patients will return to a normal prescription scenario with the patient meeting the cost of their ongoing prescription needs. This will allow us to further assess the continuity of cannabis use in a ‘normal’ environment . Doctor consultation fees will be applicable during this study.
If you are a doctor and have patients who you feel may be suitable, or wish to discuss the study further, please contact CA Clinics on 1300 991 477 or email us at
